DS-1205

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC
Pharmaceutical Business Review
Fri, 10/19/18 - 10:53 pm
Daiichi Sankyo
non-small cell lung cancer
DS-1205